BioSpace News Archive

Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education, will present the 4th Annual International Congress on Immunotherapies in Cancer®: Focus on Practice-Changing Application on Saturday, Dec. 14, at the InterContinental New York Times Square in New York City.

Increasingly expansive and coercive vaccine mandates are placing the supposed collective good of society above the right of patients or their parents to give or withhold informed consent, writes Jane M. Orient, M.D., in a guest editorial in the fall issue of the Journal of American Physicians and Surgeons.

Healthfirst, New York’s largest not-for-profit health insurance company with nearly 1.4 million members, launched a brand campaign today with a look and feel that is a significant departure from the past.

Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel therapies that regulate select integrin functions for the treatment of ocular diseases, today announced that the results of its U.S. Phase 2 study evaluating risuteganib (Luminate®) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during the 19th European Society of Retina Specialists (EURETINA) Congress

One Mind has announced the five winners of its 2019 One Mind Rising Star Awards, which identifies and funds pivotal, innovative research on the causes of and cures for brain disorders by supporting the most promising emerging leaders in the field of neuropsychiatry.

University’s 12th U.S. patent adds new compositions for CRISPR-Cas9 gene-editing technology to overall patent portfolio; expects to add five more patents in near future

Strekin AG announced that it has successfully closed a Series A financing round totaling CHF 2.82 Million from private investors.

Boehringer Ingelheim and Zealand Pharma A/S, have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand.

Planned Release of Modality-neutral NUCLeUS[1] Imaging Platform Includes Support for Multiple Formats, Including 4K Resolution, While Providing Advanced Integration and Streamlined Digital Workflows [03-September-2019] PARAMUS, N.J. , Sept. 3, 2019 /PRNewswire/ -- Sony plans to release a new, more user-friendly workflow version of its modality-neutral NUCLeUS ™ medic

GB Sciences, Inc. announced that it has received notification from the U.S. Drug Enforcement Agency that prior to making any decisions on the pending applications, the DEA intends to distribute regulations that govern the program of growing marijuana for scientific research under DEA registration.